United States - English - NLM (National Library of Medicine)

major pharmaceuticals - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - hypertension: captopril tablets, usp, are indicated for the treatment of hypertension. in using captopril tablets, usp, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings ). captopril tablets, usp may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets, usp are effective alone and in combination with other antihypertensive agents, especially thiazidetype diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. heart failure: captopril tablets, usp are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril i

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril tablets, usp are indicated for the treatment of hypertension. in using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings). captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type i insulin-dependent diabetes mellitus and retinopathy. captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). in considering use of captopril tablets, it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, ace inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see warnings: head and neck angioedema and intestinal angioedema). captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin-converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). do not co-administer aliskiren with captopril in patients with diabetes (see precautions: drug interactions). captopril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer captopril within 36 hours of switching to or from sacubitril/valsartan, a nepriltsin inhibitor (see precautions, drug interactions).

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril tablets, usp are indicated for the treatment of hypertension. in using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings). captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type i insulin-dependent diabetes mellitus and retinopathy. captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). in considering use of captopril tablets, it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, ace inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see warnings: head and neck angioedema and intestinal angioedema). captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin-converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). do not co-administer aliskiren with captopril in patients with diabetes (see precautions: drug interactions). captopril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer captopril within 36 hours of switching to or from sacubitril/valsartan, a nepriltsin inhibitor (see precautions, drug interactions).

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril tablets, usp are indicated for the treatment of hypertension. in using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings). captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type i insulin-dependent diabetes mellitus and retinopathy. captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). in considering use of captopril tablets, it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, ace inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see warnings: head and neck angioedema and intestinal angioedema). captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin-converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). do not co-administer aliskiren with captopril in patients with diabetes (see precautions: drug interactions). captopril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer captopril within 36 hours of switching to or from sacubitril/valsartan, a nepriltsin inhibitor (see precautions, drug interactions).

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril tablets, usp are indicated for the treatment of hypertension. in using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings). captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type i insulin-dependent diabetes mellitus and retinopathy. captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). in considering use of captopril tablets, it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, ace inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see warnings: head and neck angioedema and intestinal angioedema). captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin-converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). do not co-administer aliskiren with captopril in patients with diabetes (see precautions: drug interactions). captopril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer captopril within 36 hours of switching to or from sacubitril/valsartan, a nepriltsin inhibitor (see precautions, drug interactions).

United States - English - NLM (National Library of Medicine)

solco healthcare us, llc - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - hypertension: captopril tablets, usp are indicated for the treatment of hypertension. in using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings ). captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. heart failure: captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

krka d.d. - captopril - tablets - 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - captopril - oral tablet - 12.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - captopril - oral tablet - 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - captopril - oral tablet - 50mg